Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,518 questions in 135 reviews · Infectious Diseases
current versionsNo studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Treatment failure · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | RR 1.28 [0.82, 2] | 7 studies · 3606 participants | Moderate |
Intervention NR Relapse · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | RR 1.28 [1, 1.64] | 10 studies · 3621 participants | Low |
Intervention NR Death · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | RR 0.96 [0.67, 1.39] | 11 studies · 4800 participants | Moderate |
Intervention NR Sputum smear or culture conversion at end of treatment · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | RR 0.99 [0.96, 1.02] | 7 studies · 2319 participants | High |
Intervention NR Serious adverse events · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | RR 1.45 [0.9, 2.33] | 6 studies · 3388 participants | Moderate |
Intervention NR Adverse events leading to discontinuation of therapy · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | RR 0.96 [0.56, 1.66] | 13 studies · 5530 participants | Low |
Intervention NR Combined endpoint of treatment failure, relapse, or death** · treating pulmonary TB Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Test result GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR False positives (patients incorrectly classified as having SLID resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 8 studies · 1291 participants | Moderate |
Intervention NR Test result GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR True positives (patients correctly diagnosed with XDR‐TB) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 6 studies · 143 participants | Low |
Intervention NR False negatives (patients incorrectly classified as not having XDR‐TB) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 6 studies · 143 participants | Low |
Intervention NR True negatives (patients correctly classified as not having XDR‐TB) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 6 studies · 1277 participants | Moderate |
Intervention NR False positives (patients incorrectly classified as having XDR‐TB) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 6 studies · 1277 participants | Moderate |
Intervention NR True positives (patients correctly diagnosed with FQ resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 9 studies · 519 participants | Moderate |
Intervention NR False negatives (patients incorrectly classified as not having FQ resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 9 studies · 519 participants | Moderate |
Intervention NR True negatives (patients correctly classified as not having FQ resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 9 studies · 1252 participants | High |
Intervention NR False positives (patients incorrectly classified as having FQ resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 9 studies · 1252 participants | High |
Intervention NR Test result GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR True positives (patients correctly diagnosed with SLID resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 8 studies · 348 participants | Low |
Intervention NR False negatives (patients incorrectly classified as not having SLID resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 8 studies · 348 participants | Low |
Intervention NR True negatives (patients correctly classified as not having SLID resistance) GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs (2016) · Cochrane | no estimate extracted | 8 studies · 1291 participants | Moderate |
Directly observed therapy (DOT) vs self‐administered TB treatment Cure · Patients on TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1.08 [0.91, 1.27] | 5 studies · 1645 participants | Moderate |
Directly observed therapy (DOT) vs self‐administered TB treatment Treatment completion · Patients on TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1.07 [0.96, 1.19] | 6 studies · 1839 participants | Moderate |
Home DOT vs clinic DOT Cure · Patients with TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1.02 [0.88, 1.18] | 4 studies · 1556 participants | Moderate |
Home DOT vs clinic DOT Treatment completion4 · Patients with TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1.04 [0.91, 1.17] | 3 studies · 1029 participants | Moderate |
Intervention NR Cure · Patients on TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1.02 [0.86, 1.21] | 2 studies · 1493 participants | Moderate |
Intervention NR Treatment completion · Patients on TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1.05 [0.9, 1.22] | 2 studies · 1493 participants | Low |
DOT vs self‐administered therapy Treatment completion · Patients on TB treatment Directly observed therapy for treating tuberculosis (2015) · Cochrane | RR 1 [0.88, 1.13] | 1 study · 300 participants | Low |
Intervention NR Diarrhoea episodes · adults and children Interventions to improve water quality for preventing diarrhoea (2015) · Cochrane | RR 0.77 [0.65, 0.91] | 14 studies · 30746 participants | Low |
Intervention NR Cure or completion of treatment for active TB · Recipients of TB control services Incentives and enablers to improve adherence in tuberculosis (2015) · Cochrane | RR 1.04 [0.97, 1.13] | 2 studies · 4356 participants | Low |
Intervention NR Completion of TB prophylaxis · Recipients of TB control services Incentives and enablers to improve adherence in tuberculosis (2015) · Cochrane | no estimate extracted | 3 studies · 869 participants | Low |
Intervention NR Return to clinic to start or continue treatment · Recipients of TB control services Incentives and enablers to improve adherence in tuberculosis (2015) · Cochrane | RR 1.58 [1.27, 1.96] | 3 studies · 595 participants | Moderate |
Intervention NR Return for tuberculin skin test reading · Recipients of TB control services Incentives and enablers to improve adherence in tuberculosis (2015) · Cochrane | RR 2.16 [1.41, 3.29] | 2 studies · 1371 participants | Low |
Intervention NR Vector density · People at risk of cutaneous leishmaniasis (CL) or visceral leishmaniasis (VL) Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 4 studies · 4 participants | Moderate |
Intervention NR Vector density · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 1 study · 1 participants | Very low |
Intervention NR CL cases > 12 months · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | RR 0.34 [0.2, 0.57] | 1 study · 2784 participants | Low |
Intervention NR VL cases > 2 years · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Vector density · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR CL cases > 12 months · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | RR 0.4 [0.13, 1.2] | 2 studies · 558 participants | Low |
Intervention NR VL cases > 2 years · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Vector density · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR CL cases 12 months · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | RR 0.42 [0.13, 1.41] | 1 study · 3631 participants | Very low |
Intervention NR VL cases > 2 years · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Intervention NR Vector density · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 2 studies · 2 participants | Low |
Intervention NR CL cases > 12 months · People at risk of cutaneous leishmaniasis (CL) or visceral leishmaniasis (VL) Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | RR 0.61 [0.38, 0.97] | 1 study · 2892 participants | Moderate |
Intervention NR CL cases > 12 months · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | RR 1.9 [0.98, 3.69] | 1 study · 1655 participants | Low |
Intervention NR VL cases > 2 years · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR VL cases > 2 years · People at risk of cutaneous leishmaniasis (CL) or visceral leishmaniasis (VL) Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Vector density · People at risk of CL or VL Vector and reservoir control for preventing leishmaniasis (2015) · Cochrane | no estimate extracted | 3 studies · 3 participants | Low |